Evidence map›Paper›PMID 37849534›Full record

ArticleACS medicinal chemistry letters2023

Unleashing the Potential of 1,3-Diketone Analogues as Selective LH2 Inhibitors.

Juhoon Lee, Hou-Fu Guo, Shike Wang, Yazdan Maghsoud, Erik Antonio Vázquez-Montelongo, Zhifeng Jing, Rae M Sammons, Eun Jeong Cho, Pengyu Ren, G Andrés Cisneros and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Juhoon LeeDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.ORCID https://orcid.org/0000-0001-7178-4226
Hou-Fu GuoDepartment of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, Kentucky 40536, United States.
Shike WangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Yazdan MaghsoudDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, Texas 75080, United States.ORCID https://orcid.org/0000-0002-4051-0844
Erik Antonio Vázquez-MontelongoDepartment of Physical Medicine and Rehabilitation, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.ORCID https://orcid.org/0000-0001-5253-7887
Zhifeng JingDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID https://orcid.org/0000-0001-7013-036X
Rae M SammonsDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Eun Jeong ChoDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
Pengyu RenDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID https://orcid.org/0000-0002-5613-1910
G Andrés CisnerosDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, Texas 75080, United States.ORCID https://orcid.org/0000-0001-6629-3430
Jonathan M KurieDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Kevin N DalbyDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.ORCID https://orcid.org/0000-0001-9272-5129
Target (United States) · USThe University of Texas at Austin · USThe University of Texas at Dallas · USThe University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · USUniversity of Kentucky · US

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
University of Kentucky Center for Cancer MetabolismP20GM121327 · NIGMS · UNIVERSITY OF KENTUCKY · PI Binhua P Zhou · 2017 to 2026
$25.0M
DEVELOPMENT OF A NEXT-GENERATION NUCLEIC ACID FORCE FIELDR01GM106137 · NIGMS · WASHINGTON UNIVERSITY · PI JAY PONDER, Pengyu Ren · 2013 to 2026
$3.5M
Theory and Simulation of DNA Repair Enzymes; Mechanism, Structure and FunctionR01GM108583 · NIGMS · WAYNE STATE UNIVERSITY · PI CISNEROS, GERARDO ANDRES · 2014 to 2022
$2.9M
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2R01CA251067 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2021 to 2025
$2.7M
Specificity and Selectivity in Protein-Ion BindingR01GM114237 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI PONDER, JAY, REN, PENGYU · 2015 to 2023
$2.6M
Determining structural features of a collagen lysyl hydroxylase that promotes lung cancer metastasisR00CA225633 · NCI · UNIVERSITY OF KENTUCKY · PI GUO, HOUFU · 2020 to 2022
$730k
NCI NIH HHS P50 CA070907NCI NIH HHS R00 CA225633NCI NIH HHS R01 CA251067NIGMS NIH HHS P20 GM121327NIGMS NIH HHS R01 GM106137NIGMS NIH HHS R01 GM108583NIGMS NIH HHS R01 GM114237
6 · The paper itself

Abstract

Lysyl hydroxylase 2 (LH2) catalyzes the formation of highly stable hydroxylysine aldehyde-derived collagen cross-links (HLCCs), thus promoting lung cancer metastasis through its capacity to modulate specific types of collagen cross-links within the tumor stroma. Using

Identifiers

PMID37849534
PMCPMC10577891
OpenAlexW4386951268

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.